Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Old API Wind-down Ltd - Ordinary Shares ARLZQ

Healthcare Drug Manufacturers - Major Drug Manufacturers - Specialty & Generic
"Old API Wind-down Ltd, formerly Aralez Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in the acquisition, development, and commercialization of products primarily in cardiovascular, pain management and other specialty areas. Its key products include Fiorinal, Proferrin, Fibricor, Uracyst and Neovisc, Cambia and other marketed products. The company currently operates in two geographical markets, the United States and Canada. The firm generates most of its reven


OTCPK:ARLZQ - Post by User

Old API Wind-down Ltd - Ordinary Shares
Bullboard Posts
User Avatar Image
(0)
•••
Comment by clestoron Mar 23, 2013 10:05pm
193 Views
Post# 21159398

RE: RE: RE: RE: RE: RE: RE: Firday hearing

RE: RE: RE: RE: RE: RE: RE: Firday hearing

My read of the merger aggrement is that if ARZ shareholders don't approve the HL transaction, then ARZ only reimbures HL for its expenses to a maximum of $8 mm . . . but maybe their expenses were less than half that.  Getting 66.67% is no slam dunk given large portion held by retail investors.

If I were AGI, I would hold onto my shares . . . see if the stock falls out of bed if the HL deal fails, and start accumulating again.

Make sense?

Bullboard Posts
Dealroom for high-potential pre-IPO opportunities